Alabama is currently home to 1237 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Birmingham, Mobile, Huntsville and Anniston. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Absorption and Tolerability of Injectable Administration of Niagen®+, as Compared to NAD+
NCT06919328
Recruiting
This study evaluates the subjective effects of injection administration of NR on healthy adult populations.
Gender:
ALL
Ages:
Between 40 years and 65 years
Trial Updated:
04/07/2025
Locations: Nutraceuticals Research Institute, Huntsville, Alabama
Conditions: Healthy Aging
Register for Updates
Assessment of Metformin for Restoration of Immune Homeostasis in HIV+ and HIV- Individuals With a History of Injection Drug Use
NCT06829238
Recruiting
This randomized clinical trial (RCT) evaluates whether metformin can reduce systemic inflammation and improve immune function in individuals with a history of injection drug use, with or without HIV. Participants will receive metformin or placebo and undergo immune system assessments, including vaccine response evaluations.
Gender:
ALL
Ages:
Between 18 years and 64 years
Trial Updated:
04/04/2025
Locations: University of Alabama at Birmingham, Birmingham, Alabama
Conditions: Systemic Inflammation, Immune Dysregulation, Injection Drug Use, HIV
Register for Updates
Shockwave Lithoplasty Compared to Cutting Balloon Treatment in Calcified Coronary Disease - A Randomized Controlled Trial
NCT06089135
Recruiting
The Short-Cut trial is a prospective, investigator-initiated, multicenter, randomized controlled trial that is designed to compare the efficacy of cutting balloon angioplasty vs. intravascular lithotripsy prior to drug-eluting stent implantation in patients with moderate to severely calcified coronary arteries.
Gender:
ALL
Ages:
21 years and above
Trial Updated:
04/03/2025
Locations: UAB Structural Heart and Valve Clinic, Birmingham, Alabama
Conditions: Treatment in Calcified Coronary Disease
Register for Updates
Study of Lenacapavir and Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) in Prevention of HIV in Cisgender Women in the United States (HPTN 102)
NCT06101329
Recruiting
The goal of this clinical study is to look at how lenacapavir (LEN) passes through the body and to assess the safety of LEN and emtricitabine/tenofovir disoproxil fumarate (F/TDF) for prevention of HIV in the cisgender women in the US. The primary objectives of this study are: 1) to characterize the pharmacokinetics (PK) of LEN in United States (US) cisgender women; 2) to evaluate the safety of LEN and F/TDF for pre-exposure prophylaxis (PrEP) in US cisgender women; and 3) to evaluate the gener... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
04/01/2025
Locations: UAB, 1917 Research Clinic, Birmingham, Alabama
Conditions: Pre-Exposure Prophylaxis of HIV Infection
Register for Updates
PRE-I-SPY Phase I/Ib Oncology Platform Program
NCT05868226
Recruiting
I-SPY Phase I/Ib (I-SPY-P1) is an open-label, multisite platform study designed to evaluate single agents or combinations in a metastatic treatment setting that may be relevant for breast cancer patients with the overall goal of moving promising drug regimens into the I-SPY 2 SMART Design Trial (NCT01042379) and/or other oncology-based trials in a timely manner.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/01/2025
Locations: The University of Alabama at Birmingham O'Neal Comprehensive Cancer Center, Birmingham, Alabama
Conditions: HER2-positive Breast Cancer, Metastatic Cancer, Metastatic Breast Cancer, Metastatic, HER2-positive Metastatic Breast Cancer, HER2 Mutation-Related Tumors, HER-2 Protein Overexpression, HER2-negative Breast Cancer, Triple Negative Breast Cancer, HR Positive, Hormone Receptor-positive Breast Cancer, Estrogen Receptor Positive Tumor, Progesterone Receptor-positive Breast Cancer, Hormone Receptor Negative Breast Carcinoma, Solid Tumor, Solid Tumor, Adult, Solid Carcinoma, HER2 Low Breast Cancer, HER2 Low Breast Carcinoma, ER Positive Breast Cancer, PR-positive Breast Cancer
Register for Updates
Study to Evaluate the Safety and Efficacy of Daily Subcutaneous Metreleptin Treatment in Subjects With PL
NCT05164341
Recruiting
This is a Phase III, double-blind, placebo-controlled, safety and efficacy study of daily SC metreleptin in subjects with Partial Lipodystrophy.
Gender:
ALL
Ages:
12 years and above
Trial Updated:
04/01/2025
Locations: University of Alabama, Birmingham, Alabama
Conditions: Partial Lipodystrophy
Register for Updates
Strengthening Health and Insight in New Educators
NCT06745934
Recruiting
Teachers are at notable risk for depression and anxiety. The present study tests an app-based mindfulness intervention for teachers in their final year of training with the goal of preventing the deterioration of their mental health during the transition into the classroom. The project will strengthen the research environment at the University of Alabama and will involve undergraduate research assistants in each step of the research process.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/31/2025
Locations: University of Alabama, Tuscaloosa, Alabama
Conditions: Anxiety Symptoms, Depressive Symptoms
Register for Updates
BeFit Toolbox Collaboration: Building Empowerment Through Fitness
NCT06293846
Recruiting
This project will identify the causative behavioral factors in low-income African American women leading to sedentarism, a major source of morbidity in HABD communities. Working with our partner, WUCN, we will engage with women in HABD housing to develop and (later) deliver a physical activity education program (BeFit) customized for this population.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
03/31/2025
Locations: University of Alabama at Birmingham, Birmingham, Alabama
Conditions: Low-Income Population, Women's Health
Register for Updates
IMPRoving Outcomes in Vascular DisEase- Aortic Dissection
NCT06087029
Recruiting
The goal of this clinical trial is to determine whether an upfront invasive strategy of TEVAR plus medical therapy reduces the occurrence of a composite endpoint of all-cause death or major aortic complications compared to an upfront conservative strategy of medical therapy with surveillance for deterioration in patients with uncomplicated type B aortic dissection.
Gender:
ALL
Ages:
21 years and above
Trial Updated:
03/31/2025
Locations: University of Alabama at Birmingham, Birmingham, Alabama
Conditions: Type B Aortic Dissection
Register for Updates
Decellularized Femoral Artery Allograft (Nexeon AVX) Prospective Registry
NCT05880537
Recruiting
Post market registry to assess the safety and efficacy of a novel decellularized human femoral artery allograft (Nexeon AVX Decellularized Femoral Artery,
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/28/2025
Locations: Infirmary Heath, Mobile, Alabama
Conditions: End-Stage Renal Disease
Register for Updates
mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma
NCT05677490
Recruiting
This phase III trial compares the effect of modified fluorouracil, leucovorin calcium, oxaliplatin, and irinotecan (mFOLFIRINOX) to modified fluorouracil, leucovorin calcium, and oxaliplatin (mFOLFOX) for the treatment of advanced, unresectable, or metastatic HER2 negative esophageal, gastroesophageal junction, and gastric adenocarcinoma. The usual approach for patients is treatment with FOLFOX chemotherapy. Chemotherapy drugs work in different ways to stop the growth of tumor cells, either by k... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/28/2025
Locations: University of Alabama at Birmingham Cancer Center, Birmingham, Alabama
Conditions: Advanced Esophageal Adenocarcinoma, Advanced Gastric Adenocarcinoma, Advanced Gastroesophageal Junction Adenocarcinoma, Clinical Stage III Esophageal Adenocarcinoma AJCC v8, Clinical Stage III Gastric Cancer AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IV Esophageal Adenocarcinoma AJCC v8, Clinical Stage IV Gastric Cancer AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Metastatic Esophageal Adenocarcinoma, Metastatic Gastric Adenocarcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma, Unresectable Esophageal Adenocarcinoma, Unresectable Gastric Adenocarcinoma, Unresectable Gastroesophageal Junction Adenocarcinoma
Register for Updates
Targeting Minority Stressors to Improve Eating Disorder Symptoms in Sexual Minority Individuals With Eating Disorders
NCT06565637
Recruiting
The goal of this clinical trial is to learn if a new intervention (Promoting Resilience to Improve Disordered Eating; PRIDE) can decrease internalized stigma and increase the ability to cope effectively with stressors in sexual minority populations diagnosed with eating disorders. The main question it aims to answer is: Will an eating disorders treatment focused on decreasing internalized stigma and increasing sexual minority stress coping self efficacy in sexual minority populations? Participa... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
03/27/2025
Locations: Auburn University, Auburn, Alabama
Conditions: Eating Disorders, Sexual Minorities
Register for Updates